Old Articles: <Older 31-40 Newer> |
|
The Motley Fool February 7, 2005 Stephen D. Simpson |
Bright, But Not Bold, Clorox Steady but unspectacular growth might leave investors wanting a bit more kick. |
The Motley Fool January 28, 2005 Rich Smith |
The Tao of Dow Overall, and despite a slew of one-time benefits and charges that skew the results somewhat, Dow Chemical managed to increase its profits by 57% in comparison to its 2003 results, earning its shareholders $2.93 per diluted share in 2004. |
The Motley Fool January 25, 2005 Stephen D. Simpson |
DuPont Stays the Course The giant chemical company reports satisfactory earnings, despite a flurry of charges. |
The Motley Fool January 21, 2005 Stephen D. Simpson |
Cytec Rides the Cycle Specialty chemicals maker Cytec enjoys a strong quarter because of a cyclical run. |
BusinessWeek January 24, 2005 Laura Cohn |
Why It Pays To Reinvent The Mop U.K.-based Reckitt-Benckiser isn't a household word, but it's a cleaning-products superstar. Its stock has more than doubled since 2000, to $29. |
The Motley Fool January 18, 2005 Tom Taulli |
Celanese Leaves Investors Scraps This global integrated producer of value-added industrial chemicals is either No. 1 or No. 2 in the markets it focuses on and its IPO is a killer deal for private equity group Blackstone. But what about others? |
The Motley Fool January 6, 2005 W.D. Crotty |
RPM = Really Positive Momentum RPM, a holding company that is a world leader in specialty coatings and sealants, reports record revenue and income. For asbestos-tolerant investors, it is a long-term performer worth investigating. |
The Motley Fool December 6, 2004 Rich Smith |
How Now, Dow? Gullible BBC fumbles story on Dow Chemical. The con's originator may be looking at both civil and criminal liability for stock manipulation as well as wire fraud charges, as his tactic bears many of the hallmarks of "phishing." |
The Motley Fool December 2, 2004 W.D. Crotty |
Nothing to Pall Over Filtration, separation, and purification giant Pall reported an 11% increase in revenue for the first fiscal quarter. While Pall is the global leader in its markets, there is mounting competition from industrial giants. |
The Motley Fool November 29, 2004 Brian Gorman |
Glass Half Full for Bayer Bayer is battling drug recall demons, but the company's positives seem to outweigh its negatives. The German drug and chemical giant posted a net profit of $42 million, reversing a massive loss recorded in the same period last year. |
<Older 31-40 Newer> Return to current articles. |